topotecan has been researched along with veliparib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ames, M; Bonner, W; Carter, J; Chen, A; Doroshow, JH; Hollingshead, M; Ji, J; Jia, L; Kinders, R; Kummar, S; Melillo, G; Murgo, AJ; Parchment, RE; Pommier, Y; Reid, JM; Rubinstein, L; Speranza, G; Stotler, H; Tomaszewski, JE; Wang, L; Weil, M; Zhang, Y | 1 |
| Chen, AP; Doroshow, JH; Kummar, S; Nguyen, D; Pommier, Y; Rubinstein, L; Tomaszewski, JE; Voeller, D; Yang, SX; Zajac-Kaye, M | 1 |
| Dai, NT; Flatten, KS; Kaufmann, SH; McDonald, JS; Patel, AG; Poirier, GG; Schneider, PA | 1 |
| Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE | 1 |
| Bender, DP; Carter, JS; Dawson, D; Deng, W; Gray, HJ; Guaglianone, PP; Kunos, C; Lea, JS; Moore, KN; Zanotti, KM | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Doles, JD; Hogan, KA; Huston, O; Jatoi, A; O'Connor, J; Wahner Hendrickson, AE | 1 |
| Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD | 1 |
| Pommier, Y; Thomas, A | 1 |
2 review(s) available for topotecan and veliparib
| Article | Year |
|---|---|
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Targeting Topoisomerase I in the Era of Precision Medicine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; DNA Topoisomerases, Type I; Humans; Irinotecan; Molecular Targeted Therapy; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Precision Medicine; Topoisomerase I Inhibitors; Topotecan | 2019 |
3 trial(s) available for topotecan and veliparib
| Article | Year |
|---|---|
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Drug Administration Schedule; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasms; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |
A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Cycle Proteins; Disease Progression; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Recombinant Proteins; Ribonucleotide Reductases; Thrombocytopenia; Topotecan; Uterine Cervical Neoplasms | 2015 |
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan | 2018 |
5 other study(ies) available for topotecan and veliparib
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Checkpoints; Cell Death; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; DNA Repair; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Signal Transduction; Staurosporine; Time Factors; Topotecan; Tumor Suppressor Protein p53 | 2011 |
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Embryo, Mammalian; Fibroblasts; Humans; Mice; Mice, Knockout; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase I Inhibitors; Topotecan | 2012 |
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan | 2013 |
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.
Topics: Adult; Aged; Benzimidazoles; Cachexia; Female; Humans; Male; Middle Aged; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prospective Studies; Tomography, X-Ray Computed; Topoisomerase Inhibitors; Topotecan; Weight Loss | 2018 |